Thrombotic ACC tab. p / o captivity. ksh / sol. 50 mg # 100
Package quantity, pcs:
28
one hundred
Dosage:
100mg
50mg
Category
Anticoagulants
Scope of the medicinal product
Heart, vessels, blood
Release form
Tablet
Manufacturer country
Austria
Package quantity, pcs
one hundred
Release form, composition and packaging
Enteric film coated tablets of white color, round, biconvex
with a shiny, smooth or slightly rough surface.
1 tab.
acetylsalicylic acid 50 mg
Excipients: lactose monohydrate - 65 mg, microcrystalline cellulose - 28.5 mg, colloidal silicon dioxide - 1.5 mg, potato starch - 5 mg.
Shell composition: talc - 2.53 mg, triacetin - 680 μg, copolymer of methacrylic acid and ethyl acrylate (1: 1) (Eudragit L) - 6.79 mg.
Clinical and pharmacological group: NSAIDs.
Antiplatelet agent
Pharmaco-therapeutic group: Antiplatelet agent
pharmachologic effect
Acetylsalicylic acid (ASA) is an ester of salicylic acid, belongs to the group of NSAIDs.
The mechanism of action is based on the irreversible inactivation of the COX-1 enzyme, as a result of which the synthesis of prostaglandins, prostacyclins and thromboxane is blocked.
Reduces aggregation, platelet adhesion and thrombus formation by inhibiting the synthesis of thromboxane A2 in platelets.
Increases the fibrinolytic activity of blood plasma and reduces the concentration of vitamin K-dependent coagulation factors (II, VII, IX, X).
The antiplatelet effect is most pronounced in platelets, because
they are unable to re-synthesize COX.
The antiplatelet effect develops after the use of small doses of the drug and lasts for 7 days after a single dose.
These properties of ASA are used in the prevention and treatment of myocardial infarction, coronary artery disease, complications of varicose veins.
ASA also has anti-inflammatory, antipyretic and analgesic effects.
Pharmacokinetics
Suction
When taken orally, ASA is absorbed from the gastrointestinal tract quickly and completely.
The tablets are enteric coated, which reduces the direct irritant effect of ASA on the gastric mucosa.
ASA is partially metabolized during absorption.
Distribution and metabolism
During and after absorption, ASA is converted into the main metabolite, salicylic acid, which is metabolized mainly in the liver under the influence of liver enzymes to form such metabolites as phenyl salicylate, glucuronide salicylate and salicyluric acid, found in many tissues and in urine.
In women, the metabolic process is slower (less enzyme activity in the blood serum).
ASA and salicylic acid are highly bound to blood plasma proteins (from 66 to 98%, depending on the dose) and are rapidly distributed in the body.
Salicylic acid crosses the placental barrier and is excreted in breast milk.
Withdrawal
T1 / 2 ASA from blood plasma is about 15-20 minutes.
Unlike other salicylates, with repeated administration of the drug, non-hydrolyzed ASA does not accumulate in the blood serum.
Only 1% of ingested ASA is excreted by the kidneys in the form of non-hydrolyzed ASA, the rest is excreted in the form of salicylates and their metabolites.
In patients with normal renal function, 80-100% of a single dose of the drug is excreted by the kidneys within 24-72 hours.
Indications
- primary prevention of acute myocardial infarction in the presence of risk factors (such as diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age)
- secondary prevention of myocardial infarction (repeated)
- stable and unstable angina pectoris
- stroke prevention (including in patients with transient cerebrovascular accident)
- prevention of transient disorders of cerebral circulation
- prevention of thromboembolism after surgery and invasive interventions on the vessels (for example, coronary artery bypass grafting, endarterectomy of the carotid arteries, angioplasty and stenting of the coronary arteries)
- prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches (for example, with prolonged immobilization as a result of extensive
Name ENG
THROMBO ASS
Clinical and pharmacological group
NSAIDs.
Antiplatelet agent
ATX code
Acetylsalicylic acid
Dosage
50mg
Structure
1 tablet contains - acetylsalicylic acid 50 mg.
Excipients: lactose, microcrystalline cellulose, colloidal silicon dioxide, potato starch, talc, triacetin, silicone antifoam SE2, eudragit L30D (methacrylic acid and ethacrylate copolymer).
Indications
primary prevention of acute myocardial infarction in the presence of risk factors (such as diabetes mellitus, hyperlipidemia, arterial hypertension, obesity, smoking, old age)
secondary prevention of myocardial infarction (repeated)
stable and unstable angina
stroke prevention (including in patients with transient cerebrovascular accident)
prevention of transient disorders of cerebral circulation
prevention of thromboembolism after surgery and invasive interventions on the vessels (for example, coronary artery bypass grafting, carotid endarterectomy, angioplasty and coronary artery stenting)
prevention of deep vein thrombosis and thromboembolism of the pulmonary artery and its branches (for example, with prolonged immobilization as a result of extensive surgery).
Contraindications
erosive and ulcerative lesions of the gastrointestinal tract (in the acute phase)
gastrointestinal bleeding
hemorrhagic diathesis
bronchial asthma induced by the intake of salicylates and other NSAIDs
a combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses and ASA intolerance
simultaneous use with methotrexate at a dose of 15 mg per week or more
severe renal failure (CC less than 30 ml / min)
severe hepatic impairment (class B and higher on the Child-Pugh scale)
chronic heart failure III-IV functional class according to NYHA classification
pregnancy (I and III trimester)
lactation period
age up to 18 years
lactose intolerance, lactase deficiency and glucose-galactose malabsorption
hypersensitivity to ASA, excipients in the drug and other NSAIDs.
With caution: in case of gout, hyperuricemia, gastric ulcer and duodenal ulcer or gastrointestinal bleeding (in history), renal failure (CC more than 30 ml / min), liver failure (below class B on the Child-Pugh scale), bronchial asthma , chronic respiratory diseases, hay fever, nasal polyposis, drug allergies, incl. for drugs of the NSAID group, analgesics, anti-inflammatory, antirheumatic drugs pregnancy (II trimester), with a proposed surgical intervention (including minor, for example, tooth extraction) when taken simultaneously with the following drugs (methotrexate at a dose of less than 15 mg per week, anticoagulants, thrombolytic or antiplatelet agents, NSAIDs and salicylic acid derivatives in high doses digoxin oral hypoglycemic agents (sulfonylurea derivatives) and insulin valproic acid ethanol (alcoholic beverages in particular) selective serotonin reuptake inhibitors ibuprofen).
INN / Active ingredient
Acetylsalicylic acid
Storage conditions and periods
In a dry, dark place at a temperature not exceeding 25 degrees.
Expiration date: 3 years
Specifications
Category
Anticoagulants
Scope of the medicinal product
Heart, vessels, blood
Release form
Tablet
Manufacturer country
Austria
Package quantity, pcs
one hundred
Way of introduction
Through the mouth
Vacation conditions
Without recipe
Brand name
Lannacher
The amount of the dosage form in the primary package
20 pcs.
Primary packaging type
Blister
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Antiplatelet agent
Anatomical and therapeutic characteristics
B01AC06 Acetylsalicylic acid
Dosage form
Enteric film coated tablets
Dosage (volume) of the substance in the preparation
50 mg
Expiration date in days
1095
Package weight, g
ten
Mode of application
:
Thrombo ACC tablets should be taken orally, without chewing, before meals, with a small amount of liquid. < br> Assign orally at 50-100 mg 1 time / day. < br> Thrombo ACC is intended for long-term use.
The duration of therapy is determined individually.
Information on technical characteristics, delivery set, country of manufacture